FDA Clears MRI Use with Cardiac Contractility Modulation Device
The expanded 510(k) clearance from the FDA for the Optimizer Smart Mini system allows full-body MRI use for patients with heart failure who are receiving cardiac contractility modulation (CCM).
The Food and Drug Administration (FDA) has approved a 510(k) conditional clearance for whole-body magnetic resonance imaging (MRI) use in heart failure patients receiving proprietary cardiac contractility modulation (CCM) therapy with the Optimizer Smart Mini device (Impulse Dynamics).
The expanded labeling includes the use of 1.5 and 3.0 Tesla (T) full-body MRI with the Optimizer Smart Mini system, an implantable device that employs electrical pulses to facilitate heart contraction in patients with New York Heart Association (NYHA) Class III heart failure, according to Impulse Dynamics.
The company noted the Optimizer Smart Mini system was previously cleared by the FDA to improve six-minute hall walk and quality of life for those with a left ventricular ejection fraction between 25 to 45 percent and continue to experience symptoms despite receiving guideline-directed medical treatment.
Impulse Dynamics said the expanded indication for conditional MRI use is a significant benefit in this patient population.
“We are pleased to receive approval for this important labeling change reflecting a necessary option for heart failure patients who likely receive multiple surgeries and benefit from the use of MRI imaging in the course of their treatment,” noted Jason Spees, the CEO of Impulse Dynamics. “This furthers our commitment to supporting the heart failure patients who benefit from important and life changing CCM therapy with the Optimizer Smart Mini system.”
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study Says Contrast-Enhanced Mammography Offers Comparable Breast Cancer Detection to MRI
November 15th 2023In findings from an enriched cohort of asymptomatic patients with screening-detected abnormalities, researchers found that contrast-enhanced mammography (CEM) was superior to conventional mammography and offered equivalent detection of breast cancer in comparison to breast MRI and abbreviated breast MRI.
Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
November 14th 2023Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.
